Recent 8-K filings for LSTA
Highest-materiality recent filing
Lisata to be acquired by Kuva Labs for $5.00 per share plus contingent $1.00 CVR
- Kuva Labs will acquire all Lisata common shares for $5.00 cash plus one non-tradeable CVR potentially paying $1.00 upon FDA filing for certepetide.
- CVR milestone: payable if NDA is filed/accepted for certepetide within 7 years of closing; Parent must use commercially reasonable efforts.
-
Kuva Labs notifies Lisata it will not commence tender offer on June 1 as agreed; deal uncertain
On May 31, Kuva Labs told Lisata it will not start the tender offer on June 1 as previously agreed and amended.
-
Lisata amends merger: cash per share cut from $5 to $4, CVR increased to up to $3
Cash consideration reduced from $5.00 to $4.00 per share; CVR now offers up to $3.00 total ($1.25 + $1.75 milestone payments).
-
Lisata extends tender offer deadline to May 29; Kuva to pay up to $1.1M in expenses
Tender offer commencement extended from April 13 to May 29, 2026, under amended merger agreement.
-
Lisata acquisition in limbo: Kuva Labs delays tender offer, seeks new financing
Kuva Labs has not yet commenced tender offer for Lisata; deadline extended from April 3 to April 13, 2026.
-
Lisata extends tender offer deadline to April 13, 2026 per waiver
Deadline to commence tender offer moved from April 3 to April 13, 2026.
-
Lisata to be acquired by Kuva Labs for $5.00 per share plus contingent $1.00 CVR
Kuva Labs will acquire all Lisata common shares for $5.00 cash plus one non-tradeable CVR potentially paying $1.00 upon FDA filing for certepetide.
-
Lisata and Kuva extend exclusive negotiation deadline to March 7, 2026 for acquisition
Amendment to binding term sheet extends expiration from Feb 28 to March 7, 2026.
-
Lisata Therapeutics terminates exclusive license for certepetide with Qilu Pharmaceutical
Mutual termination of 2021 License and Collaboration Agreement with Qilu, effective January 23, 2026.
-
Lisata to be acquired by Kuva Labs for $4.00 cash/share + up to $2 CVRs; ~85% premium
All-cash tender offer at $4.00/share plus two non-tradeable CVRs worth up to $2/share tied to certepetide milestones.
-
Lisata reports Q3 2025 net loss $4.2M; cash runway into Q1 2027 with new partnerships
Net loss $4.2M vs $4.9M in Q3 2024; operating expenses down 17% to $4.4M.
-
Lisata posts corporate presentation for conferences; no material updates disclosed
Filed 8-K for a slide presentation dated October 14, 2025, used at investor and industry conferences.
-
Lisata grants Catalent non-exclusive license for certepetide ADC payload; up to $10.5M milestones
Granted Catalent non-exclusive license to use certepetide as ADC payload in SMARTag platform; Catalent assumes all R&D/commercial costs.
-
Net loss of $4.7M vs $5.0M in Q2 2024; revenue of $70K from Catalent license fee.
-
Lisata Therapeutics granted US composition-of-matter patent for certepetide expiring 2040
U.S. Patent No. 12,351,653 covers certepetide's chemical structure and pharmacokinetic properties.
-
Positive Cohort B ASCEND data: 6M PFS 60.8% (certepetide) vs 25% (placebo)
Cohort B: median PFS 7.5 months (certepetide) vs 4.7 months (placebo); ORR 45.2% vs 19%.
-
Lisata extends cash runway from Q3 2026 to Q4 2026
Company now expects current cash to fund operations into Q4 2026, versus prior Q3 2026 estimate.
-
CEO David Mazzo base salary increased to $717,229 from $633,032; $12,000 non-accountable expense allowance removed.
-
Lisata shareholders re-elect Azab, Klosk; approve ESPP, auditor, say-on-pay, one-year frequency
Re-elected Mohammad Azab (3,809,977 for) and Steven Klosk (3,788,000 for) as Class III directors to 2028.
-
Lisata Q1 net loss $4.7M; cash $25.8M; ASCEND Cohort B oral at ESMO-GI Jul 2025
Net loss $4.7M for Q1 2025, vs $5.4M in Q1 2024; operating expenses down 11% to $5.8M.
-
Revenue $1.0M from Kuva license (vs $0 in 2023); operating expenses down 8.9% to $23.4M.
-
Lisata reports Phase 2 ASCEND Cohort A: mOS 12.68 vs 9.72 months; 4 complete responses
Cohort A: median OS of 12.68 months for certepetide plus chemo vs 9.72 months for placebo plus chemo.
-
Lisata Therapeutics licenses certepetide to Kuva Labs for solid tumor imaging
Upfront cash license fee of $1.0M payable over 12 months in four installments.
-
Lisata Therapeutics Q3 2024 net loss $4.9M; cash runway into early 2026; multiple trial updates
Net loss of $4.9M in Q3 2024, improved from $5.3M loss in Q3 2023.
-
Lisata Therapeutics Q2 2024 net loss $5.0M; ASCEND Phase 2b top-line data expected Q4 2024
Net loss $5.0M in Q2 2024 vs $4.0M in Q2 2023; operating expenses down 19.7% to $5.5M.
-
Lisata shareholders approve all six proposals at 2024 annual meeting
Re-elected Class II directors Brown, Henson, and Mazzo; votes ranged from 3.15M to 3.26M for.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event other_material